Survival and Glycemic Control in Patients With Coexisting Melanoma and Diabetes Mellitus

Figures & data

Table 1. Characteristics of patients with melanoma.

Characteristic	All patients (n = 112)	Diabetes mellitus status
		Absent (n = 56)	Present (n = 56)	p-value
Current age, mean (SD), y	76.5 (9.9)	76.1 (9.9)	76.9 (10.1)	…^†
Age at diagnosis, mean (SD), y	69.8 (9.9)	69.8 (10.0)	69.8 (9.9)	…^†
Male sex, no. (%)	76 (67.9)	38 (67.9)	38 (67.9)	…^†
White race, no. (%)	111 (99.1)	55 (98.2)	56 (100)	0.32
Ethnicity				0.47
– Hispanic	1 (0.9)	0 (0)	1 (1.8)
– Non-Hispanic	71 (63.4)	34 (60.7)	37 (66.1)
– Unknown	40 (35.7)	22 (39.3)	18 (32.1)
BMI, mean (SD), kg/m^2	29.8 (6.7)	28.4 (6.8)	31.2 (6.3)	0.03
Married at time of cancer diagnosis, no. (%)	89 (79.5)	43 (76.8)	46 (82.1)	0.51
Payer type at time of cancer diagnosis, no. (%)				0.11
– Medicare	88 (78.6)	40 (71.4)	48 (85.7)
– Insurance	21 (18.8)	14 (25.0)	7 (12.5)
– Self pay	1 (0.9)	0 (0)	1 (1.8)
– Unknown	2 (1.8)	2 (3.6)	0 (0)
Smoking status at time of cancer diagnosis, no. (%)				0.67
– Never	48 (42.9)	25 (44.6)	23 (41.1)
– Former	55 (49.1)	25 (44.6)	30 (53.6)
– Current	6 (5.4)	4 (7.1)	2 (3.6)
– Unknown	3 (2.7)	2 (3.6)	1 (1.8)
Employment status at time of cancer diagnosis, no. (%)				0.05
– Employed	22 (19.6)	9 (16.1)	13 (23.2)
– Unemployed	7 (6.3)	3 (5.4)	4 (7.1)
– Retired	55 (49.1)	24 (42.9)	31 (55.4)
– Unknown	28 (25.0)	20 (35.7)	8 (14.3)
Eastern Cooperative Oncology Group performance status at time of cancer diagnosis, no. (%)				0.52
– 0	20 (17.9)	11 (19.6)	9 (16.1)
– 1	83 (74.1)	41 (73.2)	42 (75.0)
– 2	6 (5.4)	3 (5.4)	3 (5.4)
– 3	2 (1.8)	0 (0)	2 (3.6)
Any alcohol use at time of cancer diagnosis, no. (%)				0.28
– Yes	69 (61.6)	32 (57.1)	37 (66.1)
– No	41 (36.6)	22 (39.3)	19 (33.9)
– Unknown	2 (1.8)	2 (3.6)	0 (0)
Tumor stage, no. (%)				0.81
– I	78 (69.6)	37 (66.1)	41 (73.2)
–II	14 (12.5)	8 (14.3)	6 (10.7)
– III	12 (10.7)	7 (12.5)	5 (8.9)
– IV	7 (6.3)	4 (7.1)	3 (5.4)
–Unknown	1 (0.9)	0 (0)	1 (1.8)
Ulceration, no. (%)	16/94 (17.0)	8/47 (17.0)	8/47 (17.0)	0.99
Anatomic location, no. (%)				0.10
– Head or neck	30 (26.80)	17 (30.4)	13 (23.2)
– Upper extremity	26 (23.2)	14 (25.0)	12 (21.4)
– Torso	34 (30.4)	12 (21.4)	22 (39.3)
– Lower extremity	17 (15.2)	9 (16.1)	8 (14.3)
– Other or unknown	5 (4.5)	4 (7.1)	1 (1.8)
Corticosteroid therapy, no. (%)	7 (6.3)	2 (3.6)	5 (8.9)	0.24
Radiotherapy, no. (%)	10/110 (9.1)	6/55 (10.9)	4/55 (7.3)	0.51
Immunotherapy, no. (%)	5 (4.5)	5 (8.9)	0 (0)	0.046
Chemotherapy, no. (%)	3 (2.7)	2 (3.6)	1 (1.8)	0.57
Targeted therapy, no. (%)	4 (3.6)	3 (5.5)	1 (1.8)	0.31

^†Patients were matched by age, sex and year of melanoma diagnosis.

Table 2. Diabetes mellitus treatment for patients with melanoma (n = 52^†).

Characteristic	Value
DM diagnosis preceded melanoma diagnosis, no. (%)	46 (88.5)
Time since DM diagnosis, if it preceded the cancer diagnosis, median (range), year	11 (1–40)
DM therapy, no. (%)
– Diet management	12 (23.1)
– Oral medication	29 (55.8)
– Insulin	6 (11.5)
– Oral + insulin	4 (7.7)
Insulin use within 1 year after the cancer diagnosis, no. (%)	11 (21.1)

^†Treatment data were missing for four patients with DM.

DM: Diabetes mellitus.

Figure 1.  Overall survival.

Figure shows Kaplan–Meier survival curves after stratifying patients by DM status.

DM: Diabetes mellitus.

Figure 2.  Progression-free survival.

Figure shows Kaplan–Meier survival curves after stratifying patients by DM status.

DM: Diabetes mellitus.